Raidium, an AI-native radiology company, has launched Raidium Read (R.Read) in the U.S. to enhance imaging reviews for cancer centers, starting with Moffitt Cancer Center. This platform offers features such as whole-body lesion detection and longitudinal tracking of lesions, aiming to streamline oncology imaging workflows. As early lesion detection is crucial, especially with new WHO guidelines on cancer screening, R.Read is designed to integrate seamlessly into existing radiology practices without adding complexity. The platform is currently available for clinical trials and is awaiting regulatory clearance for broader clinical use, with expectations for approval by the end of 2026.
Thu, 16 Jul 2026 12:37:00 GMT | PR Newswire